Collaboration will harness AI technology toaddress an aging-related target

NOVATO, US - Media OutReach - August 14 , 2018 -  The Buck Institute for Research on Aging, InsilicoMedicine, and Juvenescence Ltd announced today that they have formed NapaTherapeutics, Ltd to develop drugs against a novel aging-related target. TheBuck Institute is one of the leading research centers in the world focused solelyon research on aging and the elimination of age-related disease. InsilicoMedicine is an AI company focused on a range of verticals devoted to aging.  Insilico Medicine stands to earn more than$100M in milestone payments should the program be successful. Juvenescence is acompany focused on developing drugs to modify aging and the diseases of aging.

Napa Therapeutics is based on groundbreaking research in NADmetabolism conducted in the lab of  EricVerdin, MD, President and CEO of the Buck Institute. The Verdin lab will collaboratewith Napa, using Insilico's drug development engine to speed the discovery ofnew compounds.  "This is a unique opportunity to use cutting-edge AI toaccelerate drug discovery," said Dr. Verdin. "The Buck is excited to joinforces with Insilico and Juvenescence as we work to eliminate the threat ofage-related disease for this and future generations."

"I am most excited by this model and the ability to combine thequality science of the Buck Institute with the remarkable deep learning engineat Insilico Medicine. To me this is another big step in the evolving process ofusing AI with HI (human intelligence) to extract the best of both systems," said Gregory Bailey, MD, CEO of Juvenescence. "Napa Therapeutics letsJuvenescence deepen our collaboration with the Buck Institute and with InsilicoMedicine. We hope to shorten the time required to identify molecules that canbe brought to the clinic and most importantly help patients."

"We are very happy to partner with the Buck Institute andJuvenescence around a very promising set of targets in a pathway overlooked bythe pharmaceutical industry. Aging research is among the most altruistic causesthat will improve and extend the lives of everyone on the planet and reduce thepain and suffering associated with the age-associated diseases.  However, in order to scale, our efforts mustbecome sustainable and provide reasonable returns to investors. If successful,Insilico Medicine alone stands to earn in excess of $100 million in milestonepayment from this deal", said Alex Zhavoronkov, PhD, founder and CEO ofInsilico Medicine.

About Napa Therapeutics. Ltd

Napa Therapeutics, Ltd. is a biotechnology company focused on anovel target linked to one of the fundamental processes of aging. A privatelyheld British Virgin Islands company with an office in the Isle of Man, Napa isdeveloping small molecule drugs to address this target.

About the Buck Institute for Research on Aging

Our success willultimately change healthcare. At the Buck, we aim to end the threat ofage-related diseases for this and future generations by bringing together themost capable and passionate scientists from a broad range of disciplines toidentify and impede the ways in which we age. An independent, nonprofitinstitution, our goal is to increase human health span, or the healthy years oflife. Globally recognized as the pioneer and leader in efforts to target aging,the number one risk factor for serious diseases including Alzheimer's,Parkinson's, cancer, macular degeneration, heart disease, and diabetes, the Buckwants to help people live better longer. Learn more at: https://buckinstitute.org

About Juvenescence, Ltd.

Juvenescence Limited is a company focused on developing therapiesand drugs to increase human longevity and complementary investments in relatedsectors. It was founded in 2017. The Juvenescence team are highly experiencedentrepreneurs and drug developers focused on life science and commercial drugdevelopment. Juvenescence creates new ventures and invests time and moneydirectly in both start-up and in conjunction with established longevity relatedcompanies offering operational support.

Juvenescence believes that advances in sciencehave made real the possibility of slowing, halting or potentially reversingsome elements of ageing and is assembling a pipeline of therapeutic agentsthrough joint ventures.

About Insilico Medicine, Inc.

Insilico Medicine is an artificial intelligence company withR&D offices and resources in the US, Belgium, Russia, the UK, Taiwan andKorea, sourced through hackathons and competitions. The company and itsscientists are dedicated to extending human productive longevity andtransforming every step of the drug discovery and drug development processthrough excellence in biomarker discovery, drug development, digital medicineand aging research.

Insilico pioneered the applications of thegenerative adversarial networks (GANs) and reinforcement learning forgeneration of novel molecular structures for diseases with a known ligand andwith no known targets. In addition to working collaborations with largepharmaceutical companies, the company is pursuing internal drug discoveryprograms in cancer, dermatological diseases, fibrosis, Parkinson's Disease,Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through apartnership with LifeExtension.com the company launched a range ofnutraceutical products, compounded using advanced bioinformatics and deeplearning techniques. It also provides a range of consumer-facing applications,including Young.AI.

In 2017, NVIDIA selected Insilico Medicine asone of the Top 5 AI companies for potential in social impact. In 2018, thecompany was named one of the global top 100 AI companies by CB Insights. In2018 it received the Frost & Sullivan 2018 North American ArtificialIntelligence for Aging Research and Drug Development Award accompanied byindustry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8 . https://www.insilico.com

Contact Information:

Roger Lai, Consultant

jclai@swem.com.tw